FDA Hands MindMed’s LSD Candidate Breakthrough Therapy Designation in Generalised Anxiety Disorder; Company Provides 12-Week Data and Fleshes Out Phase 3 Program Plans – Psychedelic Alpha

Psychedelic drug developer MindMed today announced that the FDA has granted breakthrough therapy designation to its LSD candidate (MM120) for the treatment of generalised anxiety disorder (GAD). The company also shared topline 12-week data from the same program, as well as results of a pharmacokinetic bridging study and further details on phase 3 study design.

In this rapid response article:

Fourth Breakthrough Therapy Designation for Psychedelics
MindMed’s 12-Week Topline Data
Looking Ahead to MM120’s Commercial Profile
Next Steps (Phase 3 Program)

This article is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

Navigating affordable approaches to cell therapy clinical trials – Pharmaceutical Technology

Share this article By Luisa Sterkel & Joana Loureiro, Tenthpin Consultants and Dr. Frank Altznauer Chief Industry Advisor at Tenthpin Despite the now evident impact of

December 1, 2023

Patients facing death are opting for a lifesaving heart device — but at what risk?

Too old and too sick for a heart transplant, Arvid Herrman was given a choice: Have a mechanical pump implanted in his heart, potentially keeping

December 19, 2023

Certain progestogens linked to higher brain tumor risk in women, study suggests

Study finds long-term use of specific progestogens increases the risk of benign brain tumors in women, while short-term use and other progestogens do not.

April 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.